Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/76446
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase
Author: Larson, R.
Yin, O.
Hochhaus, A.
Saglio, G.
Clark, R.
Nakamae, H.
Gallagher, N.
Demirhan, E.
Hughes, T.
Kantarjian, H.
le Coutre, P.
Citation: European Journal of Clinical Pharmacology, 2012; 68(5):723-733
Publisher: Springer
Issue Date: 2012
ISSN: 0031-6970
1432-1041
Statement of
Responsibility: 
Richard A. Larson & Ophelia Q. P. Yin & Andreas Hochhaus & Giuseppe Saglio & Richard E. Clark & Hirohisa Nakamae & Neil J. Gallagher & Eren Demirhan & Timothy P. Hughes & Hagop M. Kantarjian & Philipp D. le Coutre
Abstract: PURPOSE We investigated the population pharmacokinetics and exposure-response relationship of nilotinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. METHODS Nilotinib was given at 300 mg or 400 mg twice daily. Serum concentration data (sparse and full pharmacokinetic profiles) were obtained from 542 patients over 12 months. A population pharmacokinetic analysis was performed using nonlinear mixed-effect modeling. Exposure-response relationships were explored graphically or using logistic regression models. RESULTS Nilotinib concentrations were stable over 12 months. Patients in the 400 mg twice-daily arm had an 11.5% higher exposure than did those in the 300 mg twice-daily arm, and the relative bioavailability of nilotinib 400 mg twice daily was 0.84 times that of 300 mg twice daily. Patient demographics did not significantly affect nilotinib pharmacokinetics. The occurrence of all-grade total bilirubin elevation was significantly higher in patients with higher nilotinib exposure, and a positive correlation was also observed between nilotinib exposure and QTcF change on electrocardiograms from baseline. There was no significant relationship between nilotinib exposure and major molecular response at 12 months. CONCLUSIONS There is a less than proportional dose-exposure relationship between nilotinib 300 mg and 400 mg twice-daily doses. Blood level testing is unlikely to play an important role in the general management of patients with newly diagnosed CML treated with nilotinib.
Keywords: Nilotinib; Population pharmacokinetics; Exposure-response relationship; Chronic myeloid leukemia
Rights: © Springer-Verlag 2011
RMID: 0020118778
DOI: 10.1007/s00228-011-1200-7
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.